KORU Medical Systems, Inc. Common Stock (DE)

KRMD

KORU Medical Systems, Inc. (KRMD) specializes in developing and commercializing advanced infusion systems for the delivery of medication and fluids. The company focuses on designing innovative devices aimed at improving patient care and healthcare provider efficiency, particularly in the areas of fluid management and medical infusion.

$5.58 -0.10 (-1.79%)
🚫 KORU Medical Systems, Inc. Common Stock (DE) does not pay dividends

Company News

Cirtec Medical Announces Appointment of New Chief Executive Officer
GlobeNewswire Inc. • Abby Kupka • August 28, 2025

Cirtec Medical has appointed Shar Matin as its new CEO, effective September 2, 2025. Matin brings over 25 years of global leadership experience in medical technology, previously serving as CEO of Cordis and holding executive roles at multiple medical technology companies.

KORU Medical Systems Inc. (KRMD) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research • Zacks Equity Research • May 1, 2024

KORU Medical Systems Inc. (KRMD) delivered earnings and revenue surprises of 50% and 9.45%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

ClearPoint Neuro, Inc. (CLPT) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research • Zacks Equity Research • March 12, 2024

ClearPoint Neuro, Inc. (CLPT) delivered earnings and revenue surprises of 13.64% and 6.41%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

KORU Medical (KRMD) Forms New Deal on Subcutaneous Infusion
Zacks Investment Research • Zacks Equity Research • March 12, 2024

One key aspect of the collaboration of KORU Medical (KRMD) with a pharmaceutical manufacturer is the exploration of new therapeutic settings.

Silk Road Medical (SILK) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research • Zacks Equity Research • February 28, 2024

Silk Road Medical (SILK) delivered earnings and revenue surprises of 17.50% and 11.93%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Related Companies